Genmab's Darzalex could achieve peak annual sales of $9 bln -CEO

COPENHAGEN, Feb 22 (Reuters) - Danish biotech drugmaker Genmab's Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson & Johnson, has the potential to achieve annual peak annual sales as high as $13 billion, its chief executive told Reuters.